Product news

Share this article:
The FDA has approved Alcon's Patanase (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. Patanase will be available in May, Alcon said. 
 
GlaxoSmithKline and Pozen announced FDA approval of Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet combines a GSK-developed triptan designed to target migraines, with an anti-inflammatory pain reliever in single tablet form.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.